SynthesisFrontiers in surgery2024
Role of lymphadenectomy in advanced-stage ovarian cancer: a meta-analysis.
Synthesis in Frontiers in surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anatomical precision in the omics era: a proposed framework for selective para-aortic lymphadenectomy in epithelial ovarian cancer.Frontiers in medicine · 2026Review
- Development and validation of nomograms to forecast overall survival and cancer-specific survival in Asian patients diagnosed with epithelial ovarian cancer.Frontiers in surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelial Ovarian Cancer is one of the most lethal cancers among gynecologic malignancies. The disease metastasizes mainly through the peritoneal spread in the abdomen and through the lymphatic system. Lymph node involvement is present in 48% up to 75% of cases of advanced-stage ovarian cancer (ASOC). In this context, the aim of our study is to analyze the current literature on the topic and to investigate survival outcomes in patients affected by advanced-stage ovarian cancer undergoing lymphadenectomy. Methods: Following the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, we systematically searched the Pubmed and Scopus databases in June 2022 since the first publication. We made no limitations on the country. We included the studies containing disease-free survival (DFS) and Overall Survival (OS) data. Only comparative studies with a direct comparison between Lymphadenectomy and its avoidance were included for meta-analysis. Results: 18 studies fulfilled the inclusion criteria. The overall OS, DFS, and RR were comparable in the studies. 26965 patients were enrolled in the meta-analysis. Patients were analyzed concerning OS and DFS. Meta-analysis highlighted statistically significant higher OS than the lymphadenectomy group (RR 1.31 [95% CI 1.16-1.48] Conclusion: Our analysis showed a protective role of lymphadenectomy in advanced ovarian cancer, with a reduction in death risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.